Please login to the form below
BeneVir
This page shows the latest BeneVir news and features for those working in and with pharma, biotech and healthcare.
Transgene slumps as viral cancer therapy fails phase 3 trial
have tied up with Turnstone Biologics and BeneVir Biopharm, respectively.
Latest news
-
AZ invests more in IO with Transgene oncolytic virus deal
Companies such as AbbVie and J&J both struck deals in the field last year with biotech firms – Turnstone Biologics and BeneVir Biopharm respectively.
-
Vyriad inks immunotherapy alliance with Merck/Pfizer
companies. In May, Johnson &Johnson paid $140m upfront for BeneVir in a deal that could see its value head north of $1bn, while other deals have been done byand Pfizer, amongst
-
J&J moves quickly ahead with trials of myeloma CAR-T
Earlier this month it bought oncolytic virus player Benevir Biopharm for $140m upfront and up to $900m in milestones, and also has a collaboration with Aduro for cancer vaccine ADU-214
-
J&J pays $140m upfront for cancer-busting virus firm BeneVir
tumour immune response”, and the intention is clearly to test BeneVir’s candidates both alone and in combination with other drugs. ... After the acquisition goes through, BeneVir will maintain its R&D operations in Maryland, US, and become part of
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Meanwhile, AbbVie and Johnson &Johnson have both struck deals this year with biotechs in this field – Turnstone Biologics and BeneVir Biopharm respectively – suggesting the oncolytic virus sector is heating up.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Market Access Director, six figure base salary and £5K joining b...
- Highly competitive salary
- Account Manager, Healthcare Marketing Creative Agency, Fixed ter...
- Highly competitive salary
- Senior Medical Copywriter - Highly Awarded Advertising Agency
- £50,000 - £60,000 yearly
- Account Director, Healthcare Marketing Creative Agency, Fixed te...
- Highly competitive salary
- Account Manager, 6 month contract, Healthcare Brand communicatio...
- Highly competitive salary
- Home Based Account Manager, Medical Communications, UK, Pharma/M...
- Highly competitive salary
- AbbVie’s Rinvoq receives FDA approval for Crohn’s disease
- AstraZeneca announces positive phase 3 results for Tagrisso combination in lung cancer
- Bayer’s Nubeqa combination recommended by NICE to treat metastatic prostate cancer
- Bristol Myers Squibb presents positive results for idiopathic pulmonary fibrosis drug
- Novo Nordisk announces positive phase 3 results for oral weight-loss drug
- Sanofi reports positive new data for multiple sclerosis treatment tolebrutinib
- Medscape Medical Affairs Selected as Finalist for 2023 Communiqué Awards
- COVID-19: Pfizer’s Paxlovid approved by FDA and Gilead’s Veklury recommended by CHMP
- BMS and Janssen’s antithrombotic granted FDA fast track designation
- Gene therapy, gene editing and perspectives on future use in Parkinson’s disease
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
PMHub
Langland
Langland, a Publicis Health company, is the only health communications agency that thinks further across Clinical Trial Experience, Medical Strategy...
Latest intelligence
- Patient Clinical Trial & Communications Plan Review: A Customer Story
- ...
- Working together to achieve better patient pathways
- Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
- Design-thinking. Iterating for continuous improvement.
- How design can lead improvement within Pharma...
